ATLANTA, Sept. 18 Thompson Cancer Survival Center(TCSC, Knoxville, Tennessee) has placed an order for Elekta Infinity,reaffirming their long-term commitment to deliver the most advanced radiationtherapy treatments. The addition of Elekta Infinity, a linear acceleratoroptimized for Volumetric Modulated Arc Therapy (VMAT) will complement thecenter's decade-long plan to improve patient outcomes.
Chester Ramsey, Ph.D., director of medical physics at TCSC expects thetime savings with Elekta VMAT, a new treatment that targets tumors with highdoses of radiation while protecting healthy tissue, to be dramatic. "Withfixed-gantry IMRT delivery on other linear accelerators, it currently takes 7to 15 minutes to treat most of our IMRT patients. We estimate that VMATtreatment delivery times with Elekta Infinity will be reduced by at least 50percent, without compromising treatment quality."
"At TCSC, clinicians and researchers began using single rotation, constantdose rate volume modulated arc therapy more than 10 years ago," explainsRamsey, Ph.D. "The added capabilities of Elekta Infinity, such as simultaneouscontrol of gantry rotation speed, collimator rotation and variable dose ratewill advance our cancer treatment program to a new level."
TCSC currently treats 100-150 patients per day at three locations. Dr.Ramsey expects to treat up to 40 patients each day with Elekta Infinity, abouthalf of which will be VMAT treatments for prostate, head and neck, lung,esophagus and brain cancers.
In addition to Elekta Infinity, TCSC also is scheduled to install anElekta Synergy(R) linear accelerator. Elekta Synergy is an advancedmulti-functional linear accelerator that enables clinicians to image and treatpatients simultaneously.
Clinical information from all treatment systems will be streamlined withMOSAIQ(R) image-enabled oncology EMR, already in use at TCSC. MOSAIQintegrates patient information and charts from initial diagnosis and stagingthrough scheduling, planning, treatment and subsequent follow-up, maximizingefficiency and minimizing patient waiting times.
Dr. Ramsey says the new additions at TCSC will provide patients with ahigher standard of cancer care than ever before. "The clinicians andresearchers at TCSC are extremely excited about our new relationship withElekta," he adds.
Elekta is a human care company pioneering significant innovations andclinical solutions for treating cancer and brain disorders. The companydevelops sophisticated state of the art tools and treatment planning systemsfor radiation therapy and radiosurgery, as well as workflow enhancing softwaresystems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing intelligentand resource-efficient solutions that offer confidence to both healthcareproviders and patients, Elekta aims to improve, prolong and even save patientlives, making the future possible today.
Today, Elekta solutions in oncology and neurosurgery are used in over5,000 hospitals globally, and every day more than 100,000 patients receivediagnosis, treatment or follow-up with the help of a solution from the ElektaGroup.
Elekta employs around 2,500 employees globally. The corporate headquarteris located in Stockholm, Sweden, and the company is listed on the NordicExchange under the ticker EKTAb. For more information about Elekta, pleasevisit www.elekta.com .
SOURCE Elekta, Inc.